HK1095762A1 - Ctgf as target for the therapy of microalbuminuriain patients with diabetic nephropathy - Google Patents

Ctgf as target for the therapy of microalbuminuriain patients with diabetic nephropathy

Info

Publication number
HK1095762A1
HK1095762A1 HK07103389A HK07103389A HK1095762A1 HK 1095762 A1 HK1095762 A1 HK 1095762A1 HK 07103389 A HK07103389 A HK 07103389A HK 07103389 A HK07103389 A HK 07103389A HK 1095762 A1 HK1095762 A1 HK 1095762A1
Authority
HK
Hong Kong
Prior art keywords
diabetic nephropathy
microalbuminuriain
ctgf
therapy
patients
Prior art date
Application number
HK07103389A
Other languages
English (en)
Inventor
Flyvbjerg Allan
Guo Guangjie
David Y Liu
Thomas B Neff
Noelynn A Oliver
William R Usinger
Wang Qingjian
Original Assignee
Fibrogen Ing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Ing filed Critical Fibrogen Ing
Publication of HK1095762A1 publication Critical patent/HK1095762A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
HK07103389A 2004-02-11 2007-03-29 Ctgf as target for the therapy of microalbuminuriain patients with diabetic nephropathy HK1095762A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54412104P 2004-02-11 2004-02-11
US56101804P 2004-04-08 2004-04-08
US57840104P 2004-06-09 2004-06-09
US62080204P 2004-10-20 2004-10-20
PCT/US2005/004367 WO2005077413A1 (fr) 2004-02-11 2005-02-11 Traitement de la nephropathie diabetique ciblant le facteur de croissance des tissus conjonctifs (ctgf)

Publications (1)

Publication Number Publication Date
HK1095762A1 true HK1095762A1 (en) 2007-05-18

Family

ID=34865408

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07103389A HK1095762A1 (en) 2004-02-11 2007-03-29 Ctgf as target for the therapy of microalbuminuriain patients with diabetic nephropathy

Country Status (15)

Country Link
US (2) US20050214294A1 (fr)
EP (2) EP1977762A1 (fr)
CN (1) CN101884789A (fr)
AT (1) ATE400297T1 (fr)
AU (1) AU2005212371B2 (fr)
CA (1) CA2555789A1 (fr)
DE (1) DE602005008013D1 (fr)
DK (1) DK1715890T3 (fr)
ES (1) ES2311973T3 (fr)
HK (1) HK1095762A1 (fr)
IL (1) IL177437A (fr)
NZ (1) NZ549784A (fr)
PL (1) PL1715890T3 (fr)
PT (1) PT1715890E (fr)
WO (1) WO2005077413A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2342280A1 (fr) * 1998-09-08 2000-03-16 Henry Ford Health System Methode de detection, de prevention et de traitement de troubles renaux par modulation, regulation et inhibition du facteur de croissance du tissu conjonctif
EP1891109A1 (fr) 2005-05-05 2008-02-27 Fibrogen, Inc. Traitements des maladies cardio-vasculaires
MX2008008213A (es) * 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
MX2009006768A (es) * 2006-12-22 2009-08-31 Bellus Health Int Ltd Metodos, compuestos, y composiciones para tratar trastornos metabolicos y diabetes.
EP2190433A2 (fr) * 2007-08-22 2010-06-02 Gilead Colorado, Inc. Thérapie pour complications du diabète
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
KR101762734B1 (ko) 2008-08-25 2017-07-28 엑스칼리아드 파마슈티컬즈, 인코포레이티드 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도
CA2825059A1 (fr) 2011-02-02 2012-08-09 Excaliard Pharmaceuticals, Inc. Procede de traitement de cheloides ou de cicatrices hypertrophiees a l'aide de composes antisens ciblant un facteur de croissance de tissu conjonctif (ctgf)
CN105873608A (zh) 2013-11-28 2016-08-17 杰特有限公司 治疗肾病的方法
EP3665705A1 (fr) 2017-08-08 2020-06-17 Fresenius Medical Care Holdings, Inc. Systèmes et procédés de traitement et d'estimation de la progression d'une maladie rénale chronique
JP7152072B2 (ja) * 2018-07-31 2022-10-12 レモネックス インコーポレイテッド Ｃｔｇｆ発現抑制用組成物
CN109402127B (zh) * 2018-09-29 2021-12-10 复旦大学附属眼耳鼻喉科医院 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用
CN109453191A (zh) * 2018-12-06 2019-03-12 郑州大学第附属医院 GSK-3β抑制剂及在糖尿病肾病干预新靶点的应用
TW202110880A (zh) * 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 抗結締組織生長因子抗體及其應用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US5876730A (en) 1997-08-07 1999-03-02 Childrens Hospital Research Foundation Heparin-binding growth factor (HBGF) polypeptides
WO1999033878A1 (fr) 1997-12-25 1999-07-08 Japan Tobacco Inc. Anticorps monoclonal contre le facteur de croissance du tissu conjonctif et ses mises en applications medicales
AU4976599A (en) 1998-07-08 2000-02-01 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
CA2342280A1 (fr) * 1998-09-08 2000-03-16 Henry Ford Health System Methode de detection, de prevention et de traitement de troubles renaux par modulation, regulation et inhibition du facteur de croissance du tissu conjonctif
CN1332801A (zh) 1998-11-06 2002-01-23 法布罗根公司 结缔组织生长因子(ctgf)及应用方法
US6348329B1 (en) * 1998-11-06 2002-02-19 Fibrogen, Inc. Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
CA2354422A1 (fr) * 1998-12-14 2000-06-22 University Of Miami Fragments de facteur de croissance du tissu conjonctif, et methodes et utilisations correspondantes
US6706491B1 (en) 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
ATE526041T1 (de) 2001-12-11 2011-10-15 Fibrogen Inc Verfahren zur hemmung okularer vorgänge
EP2221054A1 (fr) 2002-04-30 2010-08-25 Alcon, Inc. Inhibiteurs de CDK pour abaisser la pression intraoculaire
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
EP1687410A4 (fr) 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc Oligonucleotides antisens optimises pour cibler le rein

Also Published As

Publication number Publication date
EP1977762A1 (fr) 2008-10-08
US20050214294A1 (en) 2005-09-29
CN101884789A (zh) 2010-11-17
CA2555789A1 (fr) 2005-08-25
ATE400297T1 (de) 2008-07-15
DE602005008013D1 (de) 2008-08-21
NZ549784A (en) 2008-06-30
WO2005077413A1 (fr) 2005-08-25
IL177437A0 (en) 2006-12-10
AU2005212371B2 (en) 2010-05-13
AU2005212371A1 (en) 2005-08-25
EP1715890B1 (fr) 2008-07-09
US20100291098A1 (en) 2010-11-18
PT1715890E (pt) 2008-10-17
US8314059B2 (en) 2012-11-20
EP1715890A1 (fr) 2006-11-02
ES2311973T3 (es) 2009-02-16
IL177437A (en) 2013-06-27
DK1715890T3 (da) 2008-11-17
PL1715890T3 (pl) 2009-01-30

Similar Documents

Publication Publication Date Title
HK1095762A1 (en) Ctgf as target for the therapy of microalbuminuriain patients with diabetic nephropathy
HRP20130707T1 (en) Compositions and uses for treating multiple sclerosis
WO2004092405A3 (fr) Gene d'hemochromatose juvenile (hfe2a), produits d'expression et leurs utilisations
MX2010004074A (es) Combinacion 059.
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
IL181304A0 (en) Dihydropteridinones for the treatment of cancer diseases
WO2006117660A3 (fr) Methode de traitement du cancer et des maladies coronaire, inflammatoire et maculaire combinant la modulation de proteines dependantes du zinc et/ou du cuivre
SG10201606441SA (en) Improved modalities for the treatment of degenerative diseases of the retina
ME01878B (me) Metodi za tretiranje upalnih bolesti
WO2010059969A3 (fr) Thérapie antiangiogenèse pour le traitement du cancer du sein
UA85559C2 (en) Aminobenzophenone compounds
ATE538800T1 (de) Kombinationstherapie zur krebsbehandlung
HK1126856A1 (en) Methods for identifying polypeptide targets
WO2005118592A8 (fr) Tetrahydropyridothiophenes utilises dans le traitement anticancereux
WO2006074187A3 (fr) Methode de traitement du cancer du cerveau
GB0521716D0 (en) Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
GB0416508D0 (en) Therapeutic agents
WO2004110245A3 (fr) Polytherapie destinee au traitement du cancer
GB0718878D0 (en) Photodynamic Theraphy and diagnosis
EP1768660A4 (fr) Composes et methodes de traitement des maladies vasculaires diabetiques
WO2006004774A3 (fr) Analogues de laulimalide en tant qu'agents therapeutiques
EP1788936A4 (fr) Dispositif catheter pour traiter l'arythmie cardiaque
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
WO2005094803A3 (fr) N3-pyridyl-thiamine et son utilisation dans le traitement du cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20240211